Literature DB >> 23430521

cblE-Type Homocystinuria Presenting with Features of Haemolytic-Uremic Syndrome in the Newborn Period.

Daniel Palanca1, Angels Garcia-Cazorla, Jessica Ortiz, Cristina Jou, Victoria Cusí, Mariona Suñol, Teresa Toll, Belén Perez, Aida Ormazabal, Brian Fowler, Rafael Artuch.   

Abstract

This study describes a cblE type of homocystinuria associated with haemolytic-uremic syndrome (HUS) features. We report on a male infant aged 43 days presenting with failure to thrive, hypotonia, pancytopaenia, HUS symptoms (microangiopathic haemolytic anaemia and thrombocytopaenia with signs of renal involvement) and fatal evolution. An underlying cobalamin disorder was diagnosed after a bone marrow examination revealed megaloblastic changes associated with hyperhomocysteinaemia. An urinary organic acid analysis revealed normal methylmalonic acid excretion. The cblE diagnosis was confirmed with a complementation analysis using skin fibroblasts and genetic studies of the MTRR gene. The patient treatment included parenteral hydroxocobalamin, carnitine, betaine and folinic acid, but there was no response. After the autopsy, the histopathological examination of the kidneys showed marked myointimal proliferation and narrowing of the vascular lumen. The central nervous system showed signs of haemorrhage that affected the putamen and the thalamus; diffuse white matter lesions with spongiosis, necrosis and severe astrogliosis were also observed. Microangiopathy was observed with an increase in vessel wall thickness, a reduction of the arterial inner diameter and capillary oedema. The signs of necrosis and haemorrhage were detected in the cerebellum, the cerebellar peduncles, the tegmentum and the bulbar olives.In conclusion, cblE should be considered when diagnosing patients presenting with HUS signs and symptoms during the newborn period. Despite early diagnosis, however, the specific treatment measures were not effective in this patient.

Entities:  

Year:  2012        PMID: 23430521      PMCID: PMC3565672          DOI: 10.1007/8904_2012_161

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  22 in total

1.  Cobalamin C defect associated with hemolytic-uremic syndrome.

Authors:  M T Geraghty; E J Perlman; L S Martin; S J Hayflick; J F Casella; D S Rosenblatt; D Valle
Journal:  J Pediatr       Date:  1992-06       Impact factor: 4.406

2.  Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator.

Authors:  G M Rodgers; W H Kane
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

3.  Vitamin B12-responsive megaloblastic anemia, homocystinuria, and transient methylmalonic aciduria in cb1E disease.

Authors:  M Tuchman; P Kelly; D Watkins; D S Rosenblatt
Journal:  J Pediatr       Date:  1988-12       Impact factor: 4.406

Review 4.  A congenital anomaly of vitamin B12 metabolism: a study of three cases.

Authors:  P Russo; J Doyon; E Sonsino; H Ogier; J M Saudubray
Journal:  Hum Pathol       Date:  1992-05       Impact factor: 3.466

5.  Rapid prenatal and postnatal detection of inborn errors of propionate, methylmalonate, and cobalamin metabolism: a sensitive assay using cultured cells.

Authors:  H F Willard; L M Ambani; A C Hart; M J Mahoney; L E Rosenberg
Journal:  Hum Genet       Date:  1976-12-15       Impact factor: 4.132

6.  Cobalamin C disease presenting as hemolytic-uremic syndrome in the neonatal period.

Authors:  Terry Kind; Joseph Levy; Margaret Lee; Shipra Kaicker; John F Nicholson; Steven A Kane
Journal:  J Pediatr Hematol Oncol       Date:  2002-05       Impact factor: 1.289

7.  [Hemolytic-uraemic syndrome. A review of 58 cases].

Authors:  A Giménez Llort; J A Camacho Díaz; J Vila Cots; A Vila Santandreu; Y Jordán García; A Palomeque Rico; M Suñol Capella
Journal:  An Pediatr (Barc)       Date:  2008-10       Impact factor: 1.500

8.  Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.

Authors:  K A Hajjar
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

9.  Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen.

Authors:  J S Stamler; J A Osborne; O Jaraki; L E Rabbani; M Mullins; D Singel; J Loscalzo
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

10.  CblE type of homocystinuria: mild clinical phenotype in two patients homozygous for a novel mutation in the MTRR gene.

Authors:  M A Vilaseca; L Vilarinho; P Zavadakova; E Vela; E Cleto; M Pineda; E Coimbra; T Suormala; B Fowler; V Kozich
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.750

View more
  4 in total

1.  An unusual cause of hypertension with hematuria and proteinuria: Answers.

Authors:  Michael B Stokes; Ronald Zviti; Fangming Lin; Vivette D D'Agati
Journal:  Pediatr Nephrol       Date:  2016-03-15       Impact factor: 3.714

2.  Clinical onset and course, response to treatment and outcome in 24 patients with the cblE or cblG remethylation defect complemented by genetic and in vitro enzyme study data.

Authors:  M Huemer; C Bürer; P Ješina; V Kožich; M A Landolt; T Suormala; B Fowler; P Augoustides-Savvopoulou; E Blair; K Brennerova; A Broomfield; L De Meirleir; G Gökcay; J Hennermann; P Jardine; J Koch; S Lorenzl; A S Lotz-Havla; J Noss; R Parini; H Peters; B Plecko; F J Ramos; A Schlune; K Tsiakas; M Zerjav Tansek; M R Baumgartner
Journal:  J Inherit Metab Dis       Date:  2014-12-20       Impact factor: 4.982

3.  Clinical, phenotypic and genetic landscape of case reports with genetically proven inherited disorders of vitamin B12 metabolism: A meta-analysis.

Authors:  Arnaud Wiedemann; Abderrahim Oussalah; Nathalie Lamireau; Maurane Théron; Melissa Julien; Jean-Philippe Mergnac; Baptiste Augay; Pauline Deniaud; Tom Alix; Marine Frayssinoux; François Feillet; Jean-Louis Guéant
Journal:  Cell Rep Med       Date:  2022-06-27

4.  A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS).

Authors:  John Rathbone; Eva Kaltenthaler; Anna Richards; Paul Tappenden; Alice Bessey; Anna Cantrell
Journal:  BMJ Open       Date:  2013-11-04       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.